Applications of ctDNA testing to monitor and detect residual disease in breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Circulating tumor DNA (ctDNA) shows promise for detecting minimal residual disease (MRD) in breast cancer patients post-treatment. Further research will clarify the clinical benefits of MRD-directed therapies.
Area Of Science
- Oncology
- Molecular Diagnostics
Background
- Circulating tumor DNA (ctDNA) is an emerging biomarker for minimal residual disease (MRD) detection in breast cancer.
- Accurate MRD detection is crucial for guiding treatment decisions and improving patient outcomes.
Purpose Of The Study
- To review current studies on ctDNA for MRD detection in breast cancer patients after curative therapy.
- To discuss limitations, future directions, and ongoing trials for MRD-directed interventions.
Main Methods
- Narrative review of existing literature on ctDNA and MRD in breast cancer.
- Analysis of studies assessing ctDNA's prognostic value and clinical utility.
Main Results
- ctDNA status demonstrates significant prognostic value across breast cancer stages and subtypes.
- The clinical utility of MRD-directed therapy guidance is still under investigation.
Conclusions
- ctDNA is a powerful tool for MRD detection and prognostication in breast cancer.
- Ongoing trials are expected to define the clinical benefit of MRD-directed therapies, optimizing breast cancer management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.